CLASS II Drug recall · Reported 13 Feb 2019 · FDA Enforcement Report

Dymista (azelastine hydrochloride recalled by Mylan Pharmaceuticals

Mylan Pharmaceuticals is recalling Dymista (azelastine hydrochloride and fluticasone propionate) Nasal Spray, 137 mcg/50 mcg, distributed nationwide in the US. The recall was initiated on 1 Feb 2019 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot: GA70535, Exp. April 2019
NDC0037-0245
Quantity recalled10,390 bottles

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0424-2019
FDA event ID
81980
Recalling firm
Mylan Pharmaceuticals, Morgantown, WV
Brand
Dymista
Manufacturer
Viatris Specialty LLC
Classification
Class II
Status
Terminated
Recall initiated
1 Feb 2019
FDA classified
4 Feb 2019
Reported
13 Feb 2019
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Foreign Material
Drug class
Nasal Sprays

Timeline

1 Feb 2019Recall initiated by company
4 Feb 2019Classified by FDA+3 days
13 Feb 2019Published in enforcement report+9 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Defective Container: Potential for broken glass in the neck area of the glass bottles.

Foreign material recalls cover pieces of metal, plastic, glass, wood or other objects that got into the product during processing and could cause injury if eaten.

Product as listed by the FDA

Dymista (azelastine hydrochloride and fluticasone propionate) Nasal Spray, 137 mcg/50 mcg per spray, 120 Metered Sprays, 23 g net fill weight bottle, Rx Only, Manufactured by: Cipla Ltd., Goa, India, M.L. No. 546; For: Meda Pharmaceuticals Inc., Somerset, New Jersey 08873-4120, NDC 0037-0245-23.

Where it was distributed

Nationwide in the USA.

Nationwide

Questions about this recall

Why was it recalled?

Defective Container: Potential for broken glass in the neck area of the glass bottles.

Which lots are affected?

Lot: GA70535, Exp. April 2019

Where was it sold?

Nationwide in the USA.

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Mylan Pharmaceuticals

All 84

Other Azelastine recalls

All 8